Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGIRI vs regorafenib in metastatic colorectal cancer (CCND1 A/A)
2024-512555-21-00Phase 3Authorised
- Sponsor
- Institut du Cancer de Montpellier
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in metastatic colon cancer (mCRC) comparing REGIRI (regorafenib + irinotecan) with Regorafenib monotherapy (2 arms). Primary endpoint: Overall survival. Planned start Jul 2024; status: authorised.
02
Drugs
regorafenibirinotecan
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on 2024-512555-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512555-21-00.